Two-Thirds of GLP-1 Weight Loss Comes Back Within a Year — Unless You Do These Things

Half of people who start a GLP-1 medication stop taking it within a year.

And on average, when they stop, they regain up to two-thirds of the weight they lost in the following 12 months.

That’s not a knock on the medication. GLP-1s are genuinely impressive tools — they reduce hunger, stabilize blood sugar, lower inflammation, and help people lose 15-20% of their body weight in a year. That’s life-changing for people with obesity and significant metabolic dysfunction.

But the data on what happens after the medication tells a story most prescribers aren’t having with their patients before they start. And it’s the story I want to walk you through, because if you’re considering a GLP-1, currently on one, or thinking about coming off one, this is the part that determines whether the tool is worth it.

My name is Alisa Turner and I’m a certified integrative health coach specializing in nutrition planning, fitness, and overall well-being. If you’re ready for clarity and a sustainable approach to a healthier life, I’m here for you. Contact me!

One quick note before I dive in: the research I’m referencing here was conducted on general populations of people with clinical obesity. That’s not exactly the population I work with. My clients are often women in perimenopause and midlife, struggling with metabolic dysfunction and the weight gain that comes with it — but not necessarily clinically obese. The studies don’t segment for that. And that matters, because how a 35-year-old man with a BMI of 38 responds to a medication is not the same as how a 47-year-old woman in perimenopause with insulin resistance, thyroid dysfunction and/or gut issues responds to it. Great research, important data — but you have to read it with your own demographic in mind, not just take the headline.

In May 2026, JAMA published new clinical guidance on lifestyle modification alongside incretin-based therapies (the umbrella term for GLP-1s, GLP-1/GIP duals like tirzepatide, and the newer triple agonists like retatrutide — you may know them simply as “GLP-1s”). The guidance was a real shift in how the medical community is positioning these medications, and much of it lines up with what I’ve seen in my practice for the last several years:

The medication produces the weight loss. But it’s the lifestyle that makes that weight loss sustainable.

Let me show you what the research says on the population they studied, and what I’d add from working with women in midlife bodies.

The JAMA paper was written by three of the biggest names in obesity medicine — Robert Kushner at Northwestern, Ariana Chao at Johns Hopkins, Thomas Wadden at Penn. Their goal was to summarize the lifestyle interventions used alongside GLP-1s in the major clinical trials, and to issue practical guidance for clinicians prescribing these medications now.

The data shows that GLP-1s alone produce 15-20% body weight loss over a year. That’s substantial, and it’s the reason these medications are being prescribed at the scale they are. But what JAMA spent most of the article on wasn’t the weight loss number. It was what they want clinicians to recommend alongside these medications — and why.

JAMA lays out what lifestyle is FOR alongside a GLP-1:

✨ Minimizing drug-related GI side effects (nausea, diarrhea — the main reason people quit)

✨ Maintaining muscle mass and bone density

✨ Preventing nutritional deficiencies

✨ Treating cardiometabolic conditions like type 2 diabetes and hypertension

✨ Supporting weight loss maintenance after the medication stops

Look at that list. None of those things happen on their own or because you took the shot. But I help clients with every single one of them.

On protein: JAMA recommends 60-75g/day, or 1.2-1.5g/kg of body weight. That’s the floor for preventing sarcopenia in the average adult population. For women in midlife — who are already losing muscle 2-3x faster than younger women, and are often in a caloric deficit on these medications — I push much higher. Typically 100g+/day, or closer to 1g per pound of goal body weight. Same principle (protect your muscle). Different population, different number.

On resistance training: JAMA recommends two or more sessions per week targeting major muscle groups. I’d say two is the minimum and three or four is better — especially if you’re using a GLP-1 in midlife, where the muscle-loss risk is amplified, or if you’ve already lost muscle because you haven’t been strength training consistently up until this point and now you’re throwing a GLP-1 into the mix.

On the discontinuation problem: approximately half of patients with obesity discontinue GLP-1 therapy within one year. JAMA noted this almost in passing. To me, this is the biggest, most underdiscussed part of the entire conversation. Which brings me to the next section.

What Happens When People Stop

About half of people who start a GLP-1 stop taking it within a year. The biggest reason, by a significant margin, is gastrointestinal side effects — nausea, vomiting, diarrhea — that become intolerable.

This is exactly where JAMA’s recommendation that lifestyle is for managing side effects becomes even more important. Half the people quitting these medications could potentially stay on them — and keep their results — if they’d only had proper coaching around food choices, meal timing, hydration, and the foods that exacerbate or relieve the GI symptoms. Or perhaps they just needed gut testing beforehand to rule out dysbiosis. This is a big deal — these are tens of thousands of people who gave up on a working medication because nobody walked them through the lifestyle side of it.

But for now, let’s stay with what happens when they do stop.

The extension data from the major semaglutide trials is the clearest picture we have. During a one-year off-treatment period following 68 weeks of semaglutide, patients regained two-thirds of the weight they’d lost. That number — two-thirds — keeps showing up across the literature on GLP-1 discontinuation.

Here’s the study that, to me, tells the most important story.

A randomized controlled trial compared four groups: liraglutide (a GLP-1) alone, structured exercise alone, both combined, and placebo. The exercise arm wasn’t a recommendation to walk more — it was 45 minutes of supervised vigorous exercise plus resistance training, twice a week — that’s structured, consistent work with an emphasis on muscle protection. After one year of treatment plus one year of follow-up off treatment, the group that took liraglutide alone regained more weight than the exercise-only group. Read that again. The medication group, after stopping, ended up worse off on maintenance than the lifestyle group.

The combined group — medication plus actual structured exercise — did the best of all.

This is the part of the GLP-1 conversation almost nobody’s having loudly enough. When people build real lifestyle infrastructure during treatment, they hold their results. When the medication is the whole plan, they don’t.

A 2026 Cleveland Clinic real-world analysis of nearly 8,000 patients reinforces this. Average regain after stopping a GLP-1 was smaller than the clinical trial data suggested — but largely because many of those patients had structured support in place: they restarted medication, switched to a different one, or got connected with ongoing lifestyle support after stopping. Regain happened when “stop the medication” was the whole plan. It didn’t happen, or happened far less, when there was a plan for what came next.

In the interest of being thorough, I do want to address one piece of research that, on the surface, seems to contradict what I’m saying here. A 2025 systematic review and meta-analysis published in Obesity Reviews concluded that GLP-1 discontinuation leads to weight regain regardless of whether lifestyle interventions were in place during treatment. That sounds contradictory until you look at what “lifestyle interventions” actually meant in those trials. In most cases, it was a monthly visit with a clinician who recommended a 500-calorie deficit and 150 minutes of weekly walking. That’s box-checking, and in my opinion not at all the right boxes were checked. There was no metabolic foundation built — strength training, sufficient protein intake, nervous system regulation, sleep architecture, gut health. The Berg meta-analysis is accurately reporting what happens when shallow lifestyle work is layered onto a GLP-1. It doesn’t tell us much about what happens when real lifestyle work is.

Which brings me back to the gap.

Most people aren’t given a plan for what comes next. They’re given a prescription, a refill schedule, and some fingers crossed 🤞 for the future.

What Truly Building the Lifestyle Looks Like

Here’s what that actually looks like, in practice.

1. Protein — helpful numbers, not the floor for malnutrition

JAMA’s recommendation of 60-75g/day, or 1.2-1.5g/kg of body weight, is the floor for preventing sarcopenia in the average adult. That’s not the number I use with clients. For women in midlife on a GLP-1, I’m typically aiming for 100g+/day, or closer to 1g per pound of goal body weight. And I’m distributing it — 40g at each meal — because muscle protein synthesis works best when you give the body enough protein at each sitting to hit the leucine threshold. Grazing on protein throughout the day doesn’t do the same thing as three real hits of it.

The other piece nobody talks about: protein on a GLP-1 is hard. The medication slows gastric emptying, which means you feel full fast and stay full longer. You physically don’t want to eat 40g of chicken breast. So we get creative — smoothies, soups, egg-based dishes, and creamy, savory sauces that cleverly disguise protein. Getting the protein in when your appetite is suppressed is not impossible. It just requires coaching and accountability.

2. Strength training — 3-4x/week is the target

JAMA says two sessions minimum. I’d call that survival, not optimization. In midlife, especially on a medication that’s putting you in a caloric deficit, you’re already losing muscle 2-3x faster than a younger woman. Two sessions a week barely holds ground. Three to four sessions, progressive overload, targeting the big muscle groups — that’s where you actually build the metabolic reserve that carries you through the transition off the medication. This is non-negotiable in my practice.

3. Hydration and electrolytes — the piece JAMA barely mentions

GLP-1s don’t just suppress hunger. They suppress thirst. You aren’t as thirsty as you should be, which means you drink less water, which means you’re chronically underhydrated — dehydration headaches, fatigue, constipation, and worsened GI symptoms are some of the top reasons people quit. Aim for consistent water intake throughout the day (not chugging a bottle at the end), and add electrolytes: sodium, potassium, and magnesium. I like the Perfect Amino electrolytes by Body Health because of the sodium:potassium ratio. You can get 10% off with code ALISATHEALTH. Proper hydration alone resolves a huge percentage of the “I feel awful on this medication” complaints I see.

4. Nervous system, gut, and the emotional flatness

There are two experiences on GLP-1s that catch people off guard, and I’ve yet to meet a client who told me they were discussed during the prescription conversation.

The first is what I call “the flatness.” The medication reduces the reward signaling from food, which is part of why it works — but it can’t select what reward it’s blunting, so it can inadvertently blunt reward signaling from other things too. Some people notice their motivation dips, their mood feels muted, activities they used to enjoy don’t bring joy anymore. This is a dopamine story, and naming it can be a real game changer for many of my clients. Managing it means being intentional about the things that build natural dopamine — strength training, morning sunlight, real social connection, sleep — because the medication is quietly turning down one of your main sources.

The second is the gut. Slowed gastric emptying plus reduced food intake plus dehydration equals bloating, constipation, and often microbiome disruption. Getting fiber in (harder than it sounds when you’re not hungry), staying hydrated, and paying attention to gut symptoms early — instead of waiting until you’re miserable — is how you avoid GI issues becoming the reason you quit. Sometimes this means running a stool test if things aren’t resolving, or preferably before you start if you have any occasional digestive symptoms. Sometimes it means specific probiotic strains or targeted support. This is the individualized part.

5. The come-off plan — start it on day one

The single biggest gap I see: people start these medications with no plan for coming off. And the data is clear that most people will come off, sooner or later, whether because of side effects, cost, insurance, pregnancy plans, or hitting a goal. So the question isn’t whether — it’s when, and what’s in place when it happens.

The come-off plan isn’t complicated in principle. It’s a customized and gradual dose reduction (not cold turkey), a locked-in food and training routine that doesn’t depend on the medication to enforce it, ongoing accountability, and an honest assessment of what appetite and cravings do when the medication starts wearing off. But it has to be built while you’re still on the medication, when things feel easy — not after you’ve stopped, when they don’t.

This is the piece that separates the people who keep their results from the people who don’t.

The bottom line is this:

If you’re on a GLP-1 or considering one, I will not be the one to talk you out of it. These medications are genuinely useful tools, and for many women in midlife struggling with metabolic dysfunction, they can be part of a smart plan if properly timed, dosed, and supported with the right lifestyle infrastructure for YOU.

But I want you to hear this clearly: the question isn’t whether you’ll come off this drug. It’s what’s underneath you when you do.

Half of people stop within a year. Most people, eventually, stop. The medication produces the weight loss. The lifestyle produces the durability. The infrastructure you build — the protein habit, the strength training routine, the hydration protocol, the nervous system practices, the gut foundation, the plan for what comes next — that’s what you’ll be standing on when the medication stops doing the lifting.

If that infrastructure isn’t there, the weight comes back. The data is clear on that. It doesn’t matter how well the medication worked while you were on it.

If that infrastructure IS there, you get to keep what you built. And in most cases, the coaching relationship that helped you build it becomes the thing that keeps you steady long after the prescription is done.

That’s the entire game.

If you’re on a GLP-1 (or thinking about one) and want help customizing the foundation that will make it work long term for YOU — that’s exactly the work I do with clients.

💬 Comment GLP1 on any of my Instagram posts and I’ll send you my free GLP-1 Metabolic Reset Starter Guide — the foundational shifts I start clients with for protecting muscle, minimizing side effects, and setting up long-term success.

📖 Want to go deeper on peptides beyond GLP-1? I wrote a full post on that here: Peptides Beyond GLP-1 [Seth: link to that post’s URL]

📅 Ready to talk it through directly? You can book a free consultation. Mount Pleasant, SC + virtual.

👋 A Gentle Reminder: I’m a functional nutritionist and metabolic health specialist, not a physician. Everything here is education and personal experience, not medical advice. GLP-1 medications, peptide therapies, and any decisions about starting, adjusting, or stopping treatment should be made with a provider who knows your full history. Please consult your doctor before starting, stopping, or changing any protocol.

References

1. Kushner RF, Chao AM, Wadden TA. Lifestyle Modification and Incretin-Based Therapy for Obesity. JAMA. 2026. https://jamanetwork.com/journals/jama/fullarticle/2849340
2. Berg S, et al. Discontinuing glucagon-like peptide-1 receptor agonists and body habitus: A systematic review and meta-analysis. Obesity Reviews. 2025. https://onlinelibrary.wiley.com/doi/10.1111/obr.13929
3. Jensen SBK, et al. Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment. eClinicalMedicine. 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC10965408/
4. Gasoyan H, et al. Real-world outcomes after discontinuation of semaglutide and tirzepatide. Diabetes, Obesity and Metabolism. 2026. https://www.medicalnewstoday.com/articles/real-world-data-outcome-stopping-glp1-drugs
5. GLP-1 agonists and exercise: the future of lifestyle prioritization. Frontiers in Endocrinology. 2025. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12683586/